Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine concizumab (brand name: Alhemo) to prevent or reduce the frequency of bleeding episodes (prophylaxis) in people aged 12 years and older with haemophilia A or B with inhibitors. Haemophilia is a rare, inherited condition that affects the way blood clots. People with haemophilia […]